Arwa Shurrab

Ms. Arwa Shurrab leads Armata’s regulatory strategy and operations team.  Arwa brings 30 years’ experience in global regulatory affairs for biologics across various therapeutic areas including infectious diseases, hematology/oncology, and rare diseases.  Her experience covers work in both small and large biotechnology companies, and includes INDs, CTAs, BLAs, MAAs and post-marketing regulatory activities.  Prior to joining Armata, Arwa was Senior Director, Strategy and Agency Liaison at ICON plc (previously PRA Health Sciences), a large global clinical research organization, where she oversaw U.S. regulatory affairs for clients from the Asia-Pacific region and other clients worldwide.  Arwa previously served as Vice President of Regulatory Affairs at Catalyst Biosciences (NASDAQ:CBIO) where she led U.S. and global activities.  Arwa also served as Director of Regulatory Affairs at Shire (acquired by Takeda), where she led the Hematology CMC team on regulatory strategy development and regulatory submissions worldwide.  Prior to Shire, Arwa spent 20 years at Baxter International, Inc. (NYSE:BAX) and Baxalta (NYSE:BXLT) leading regulatory activities, including strategy and CMC, BLA approvals and expansion to over 70 countries.  Earlier in her career, Arwa held various positions in quality control and quality assurance.  Arwa holds B.S. Degree in Chemistry with a minor in biology from the American University in Cairo (AUC).